The company plans to develop Lilly’s first-in-class clinical stage anti-angiopoietin-like 3/8 monoclonal antibody for treatment of atherosclerotic cardiovascular disease and potentially other conditions OXFORD, England & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Kyttaro announces that it has entered into an agreement for the worldwide […]